Australia registers Mounjaro for chronic weight management
An Australian regulator cleared tirzepatide for weight management, a decision that applies only in Australia and does not change US availability, pricing or labeling.
Australia's Therapeutic Goods Administration registered Mounjaro (tirzepatide) for chronic weight management on 10 September 2024, according to the agency's registration record [1]. The decision closed an evaluation that the TGA lists as 255 working days [1].
The evaluation began on 3 October 2023, and the decision date is listed as 9 September 2024, the day before the registration date [1]. The TGA records the approval time as 191, expressed as 255 working days [1]. The sponsor is Eli Lilly Australia Pty Ltd, and the active ingredient is tirzepatide [1]. The record lists a single product name, MOUNJARO, and gives the registration type as "EOI," an entry the page does not explain [1].
What the registration covers
The registered indication is chronic weight management, described as an adjunct to a reduced-calorie diet and increased physical activity, "including weight loss and weight maintenance" [1]. It applies to adults with an initial body mass index of 30 kg/m2 or higher (obesity), or an initial BMI of 27 kg/m2 to under 30 kg/m2 (overweight) when at least one weight-related condition is also present [1]. The TGA lists those conditions as hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes or type 2 diabetes mellitus [1].
The registration page is an administrative record. It does not include trial results, the amount of weight loss seen in studies, or safety findings; those details are not part of this entry [1].
Why it matters for patients
For someone weighing whether a GLP-1 or related drug is an option, this is another regulator's sign-off on tirzepatide for weight management, not new clinical evidence. The BMI structure in the Australian indication is specific: at a BMI of 27 to under 30, the registration ties coverage to having at least one of the listed conditions, while a BMI of 30 or higher does not require that additional condition under the registered wording [1].
This decision applies to the Australian market. It does not change what US regulators have approved, what US pharmacies stock, or what US insurers cover, and the TGA record does not describe availability, pricing or insurance coverage in the United States [1]. The record also does not compare tirzepatide with other medicines or state how it should be used in practice [1].
What happens next
The registration is dated 10 September 2024 [1]. The TGA page does not list a date for when the product will reach Australian pharmacies, a price, or any decision about public subsidy through the Pharmaceutical Benefits Scheme [1]. Supply arrangements and any changes to how the drug is prescribed in Australia have not been disclosed in the registration record [1]. The TGA entry also gives no timeline for reviews by other regulators [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.